Helix BioPharma Corp. (TSX: HBP.TO) Stock Competitors & Peer Comparison
See HBP.TO's competitors and their performance on the TSX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HBP.TO and its TSX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HBP.TO | CA$1.97 | -1.50% | 154.3M | -45.91 | -CA$0.04 | N/A |
| BLU.TO | CA$19.48 | -0.10% | 2.5B | -20.29 | -CA$0.96 | N/A |
| DRUG.CN | CA$108.16 | -1.14% | 1.1B | -37.42 | -CA$2.89 | N/A |
| MMED.NE | CA$14.90 | +9.48% | 1.1B | -4.50 | -CA$3.31 | N/A |
| FRX.TO | CA$15.49 | -0.90% | 538.1M | -85.85 | -CA$0.18 | N/A |
| EPRX.TO | CA$9.30 | -0.21% | 334.2M | -7.53 | -CA$1.23 | N/A |
| MSCL.TO | CA$13.51 | -2.17% | 287.5M | -5.27 | -CA$2.62 | N/A |
| ONC.TO | CA$1.42 | +2.16% | 142.3M | -3.84 | -CA$0.37 | N/A |
| MSET.CN | CA$0.74 | -1.33% | 75M | -12.33 | -CA$0.06 | N/A |
| BETR.CN | CA$0.33 | +3.17% | 52.6M | -28.02 | -CA$0.01 | N/A |
Stock Comparison
BELLUS Health Inc. (TSX: BLU.TO)
HBP.TO vs BLU.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while BLU.TO trades at CA$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, HBP.TO's ROE is -0.22%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, HBP.TO is more volatile compared to BLU.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check BLU.TO's competition here
Bright Minds Biosciences Inc. (CNQ: DRUG.CN)
HBP.TO vs DRUG.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, DRUG.CN has a market cap of 1.1B. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while DRUG.CN trades at CA$108.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas DRUG.CN's P/E ratio is -37.42. In terms of profitability, HBP.TO's ROE is -0.22%, compared to DRUG.CN's ROE of -0.13%. Regarding short-term risk, HBP.TO is more volatile compared to DRUG.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check DRUG.CN's competition here
Mind Medicine (MindMed) Inc. (NEO: MMED.NE)
HBP.TO vs MMED.NE Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MMED.NE has a market cap of 1.1B. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MMED.NE trades at CA$14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MMED.NE's P/E ratio is -4.50. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MMED.NE's ROE of -0.32%. Regarding short-term risk, HBP.TO is less volatile compared to MMED.NE. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check MMED.NE's competition here
Fennec Pharmaceuticals Inc. (TSX: FRX.TO)
HBP.TO vs FRX.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, FRX.TO has a market cap of 538.1M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while FRX.TO trades at CA$15.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas FRX.TO's P/E ratio is -85.85. In terms of profitability, HBP.TO's ROE is -0.22%, compared to FRX.TO's ROE of -0.13%. Regarding short-term risk, HBP.TO is more volatile compared to FRX.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check FRX.TO's competition here
Eupraxia Pharmaceuticals Inc. (TSX: EPRX.TO)
HBP.TO vs EPRX.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, EPRX.TO has a market cap of 334.2M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while EPRX.TO trades at CA$9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas EPRX.TO's P/E ratio is -7.53. In terms of profitability, HBP.TO's ROE is -0.22%, compared to EPRX.TO's ROE of -0.45%. Regarding short-term risk, HBP.TO is more volatile compared to EPRX.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check EPRX.TO's competition here
Satellos Bioscience Inc. (TSX: MSCL.TO)
HBP.TO vs MSCL.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MSCL.TO has a market cap of 287.5M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MSCL.TO trades at CA$13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MSCL.TO's P/E ratio is -5.27. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MSCL.TO's ROE of -0.71%. Regarding short-term risk, HBP.TO is more volatile compared to MSCL.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check MSCL.TO's competition here
Oncolytics Biotech Inc. (TSX: ONC.TO)
HBP.TO vs ONC.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, ONC.TO has a market cap of 142.3M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while ONC.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas ONC.TO's P/E ratio is -3.84. In terms of profitability, HBP.TO's ROE is -0.22%, compared to ONC.TO's ROE of -2.04%. Regarding short-term risk, HBP.TO is more volatile compared to ONC.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check ONC.TO's competition here
Mindset Pharma Inc. (CNQ: MSET.CN)
HBP.TO vs MSET.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MSET.CN has a market cap of 75M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MSET.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MSET.CN's ROE of -3.16%. Regarding short-term risk, HBP.TO is not fully comparable compared to MSET.CN. This indicates unavailable risk data in terms of short-term price fluctuations for HBP.TO.Check MSET.CN's competition here
BetterLife Pharma Inc. (CNQ: BETR.CN)
HBP.TO vs BETR.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, BETR.CN has a market cap of 52.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while BETR.CN trades at CA$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas BETR.CN's P/E ratio is -28.02. In terms of profitability, HBP.TO's ROE is -0.22%, compared to BETR.CN's ROE of +0.20%. Regarding short-term risk, HBP.TO is less volatile compared to BETR.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check BETR.CN's competition here
ProMIS Neurosciences, Inc. (TSX: PMN.TO)
HBP.TO vs PMN.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, PMN.TO has a market cap of 51.5M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while PMN.TO trades at CA$6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, HBP.TO's ROE is -0.22%, compared to PMN.TO's ROE of -8.34%. Regarding short-term risk, HBP.TO is less volatile compared to PMN.TO. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check PMN.TO's competition here
BriaCell Therapeutics Corp. (TSX: BCT.TO)
HBP.TO vs BCT.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, BCT.TO has a market cap of 48.4M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while BCT.TO trades at CA$5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas BCT.TO's P/E ratio is -0.21. In terms of profitability, HBP.TO's ROE is -0.22%, compared to BCT.TO's ROE of -1.48%. Regarding short-term risk, HBP.TO is more volatile compared to BCT.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check BCT.TO's competition here
Telescope Innovations Corp. (CNQ: TELI.CN)
HBP.TO vs TELI.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, TELI.CN has a market cap of 47.7M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while TELI.CN trades at CA$0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas TELI.CN's P/E ratio is -9.54. In terms of profitability, HBP.TO's ROE is -0.22%, compared to TELI.CN's ROE of -1.02%. Regarding short-term risk, HBP.TO is less volatile compared to TELI.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check TELI.CN's competition here
IntelGenx Technologies Corp. (TSX: IGX.TO)
HBP.TO vs IGX.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, IGX.TO has a market cap of 41.9M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while IGX.TO trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, HBP.TO's ROE is -0.22%, compared to IGX.TO's ROE of +1.27%. Regarding short-term risk, HBP.TO is less volatile compared to IGX.TO. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check IGX.TO's competition here
Sernova Corp. (TSX: SVA.TO)
HBP.TO vs SVA.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, SVA.TO has a market cap of 41.5M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while SVA.TO trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas SVA.TO's P/E ratio is -2.82. In terms of profitability, HBP.TO's ROE is -0.22%, compared to SVA.TO's ROE of +0.56%. Regarding short-term risk, HBP.TO is more volatile compared to SVA.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check SVA.TO's competition here
Microbix Biosystems Inc. (TSX: MBX.TO)
HBP.TO vs MBX.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MBX.TO has a market cap of 41.3M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MBX.TO trades at CA$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MBX.TO's P/E ratio is -8.60. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MBX.TO's ROE of -0.19%. Regarding short-term risk, HBP.TO is more volatile compared to MBX.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check MBX.TO's competition here
Sona Nanotech Inc. (CNQ: SONA.CN)
HBP.TO vs SONA.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, SONA.CN has a market cap of 40.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while SONA.CN trades at CA$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas SONA.CN's P/E ratio is -10.79. In terms of profitability, HBP.TO's ROE is -0.22%, compared to SONA.CN's ROE of +18.95%. Regarding short-term risk, HBP.TO is more volatile compared to SONA.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check SONA.CN's competition here
Defence Therapeutics Inc. (CNQ: DTC.CN)
HBP.TO vs DTC.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, DTC.CN has a market cap of 38.7M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while DTC.CN trades at CA$0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas DTC.CN's P/E ratio is -3.41. In terms of profitability, HBP.TO's ROE is -0.22%, compared to DTC.CN's ROE of -16.61%. Regarding short-term risk, HBP.TO is less volatile compared to DTC.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check DTC.CN's competition here
Resverlogix Corp. (TSX: RVX.TO)
HBP.TO vs RVX.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, RVX.TO has a market cap of 34.4M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while RVX.TO trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas RVX.TO's P/E ratio is -1.56. In terms of profitability, HBP.TO's ROE is -0.22%, compared to RVX.TO's ROE of +0.11%. Regarding short-term risk, HBP.TO is more volatile compared to RVX.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check RVX.TO's competition here
Onco-Innovations Limited (NEO: ONCO.NE)
HBP.TO vs ONCO.NE Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, ONCO.NE has a market cap of 33.4M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while ONCO.NE trades at CA$0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas ONCO.NE's P/E ratio is -2.53. In terms of profitability, HBP.TO's ROE is -0.22%, compared to ONCO.NE's ROE of N/A. Regarding short-term risk, HBP.TO is more volatile compared to ONCO.NE. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check ONCO.NE's competition here
Medicenna Therapeutics Corp. (TSX: MDNA.TO)
HBP.TO vs MDNA.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MDNA.TO has a market cap of 31.8M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MDNA.TO trades at CA$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MDNA.TO's P/E ratio is -1.86. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MDNA.TO's ROE of -3.60%. Regarding short-term risk, HBP.TO is more volatile compared to MDNA.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check MDNA.TO's competition here
Pharmala Biotech Holdings Inc. (CNQ: MDMA.CN)
HBP.TO vs MDMA.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MDMA.CN has a market cap of 28.9M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MDMA.CN trades at CA$0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MDMA.CN's P/E ratio is -42.33. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MDMA.CN's ROE of -0.72%. Regarding short-term risk, HBP.TO is less volatile compared to MDMA.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check MDMA.CN's competition here
Onco-Innovations Ltd. (CNQ: ONCO.CN)
HBP.TO vs ONCO.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, ONCO.CN has a market cap of 28.2M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while ONCO.CN trades at CA$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas ONCO.CN's P/E ratio is -65.00. In terms of profitability, HBP.TO's ROE is -0.22%, compared to ONCO.CN's ROE of -8.62%. Regarding short-term risk, HBP.TO is more volatile compared to ONCO.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check ONCO.CN's competition here
Aeterna Zentaris Inc. (TSX: AEZS.TO)
HBP.TO vs AEZS.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, AEZS.TO has a market cap of 25.4M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while AEZS.TO trades at CA$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, HBP.TO's ROE is -0.22%, compared to AEZS.TO's ROE of -0.13%. Regarding short-term risk, HBP.TO is less volatile compared to AEZS.TO. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check AEZS.TO's competition here
Lobe Sciences Ltd. (CNQ: LOBE.CN)
HBP.TO vs LOBE.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, LOBE.CN has a market cap of 19.9M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while LOBE.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas LOBE.CN's P/E ratio is -3.81. In terms of profitability, HBP.TO's ROE is -0.22%, compared to LOBE.CN's ROE of -3.39%. Regarding short-term risk, HBP.TO is more volatile compared to LOBE.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check LOBE.CN's competition here
Reunion Neuroscience Inc. (TSX: REUN.TO)
HBP.TO vs REUN.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, REUN.TO has a market cap of 16.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while REUN.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, HBP.TO's ROE is -0.22%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, HBP.TO is more volatile compared to REUN.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check REUN.TO's competition here
IMV Inc. (TSX: IMV.TO)
HBP.TO vs IMV.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, IMV.TO has a market cap of 13.1M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while IMV.TO trades at CA$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, HBP.TO's ROE is -0.22%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, HBP.TO is more volatile compared to IMV.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check IMV.TO's competition here
Rapid Dose Therapeutics Corp. (CNQ: DOSE.CN)
HBP.TO vs DOSE.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, DOSE.CN has a market cap of 12.2M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while DOSE.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas DOSE.CN's P/E ratio is -2.51. In terms of profitability, HBP.TO's ROE is -0.22%, compared to DOSE.CN's ROE of +0.47%. Regarding short-term risk, HBP.TO is less volatile compared to DOSE.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check DOSE.CN's competition here
PreveCeutical Medical Inc. (CNQ: PREV.CN)
HBP.TO vs PREV.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, PREV.CN has a market cap of 12M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while PREV.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas PREV.CN's P/E ratio is -6.31. In terms of profitability, HBP.TO's ROE is -0.22%, compared to PREV.CN's ROE of +0.23%. Regarding short-term risk, HBP.TO is more volatile compared to PREV.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check PREV.CN's competition here
Tetra Bio-Pharma Inc. (TSX: TBP.TO)
HBP.TO vs TBP.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, TBP.TO has a market cap of 10.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while TBP.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, HBP.TO's ROE is -0.22%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, HBP.TO is more volatile compared to TBP.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check TBP.TO's competition here
Britannia Life Sciences Inc. (CNQ: BLAB.CN)
HBP.TO vs BLAB.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, BLAB.CN has a market cap of 10.5M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while BLAB.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas BLAB.CN's P/E ratio is 1.53. In terms of profitability, HBP.TO's ROE is -0.22%, compared to BLAB.CN's ROE of +1.21%. Regarding short-term risk, HBP.TO is more volatile compared to BLAB.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check BLAB.CN's competition here
Glow Lifetech Corp. (CNQ: GLOW.CN)
HBP.TO vs GLOW.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, GLOW.CN has a market cap of 8.7M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while GLOW.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas GLOW.CN's P/E ratio is -2.25. In terms of profitability, HBP.TO's ROE is -0.22%, compared to GLOW.CN's ROE of -0.20%. Regarding short-term risk, HBP.TO is more volatile compared to GLOW.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check GLOW.CN's competition here
Mind Cure Health Inc. (CNQ: MCUR.CN)
HBP.TO vs MCUR.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MCUR.CN has a market cap of 7M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MCUR.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, HBP.TO is more volatile compared to MCUR.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check MCUR.CN's competition here
Core One Labs Inc. (CNQ: COOL.CN)
HBP.TO vs COOL.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, COOL.CN has a market cap of 6.8M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while COOL.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, HBP.TO's ROE is -0.22%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, HBP.TO is more volatile compared to COOL.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check COOL.CN's competition here
Aptose Biosciences Inc. (TSX: APS.TO)
HBP.TO vs APS.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, APS.TO has a market cap of 6.1M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while APS.TO trades at CA$2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas APS.TO's P/E ratio is -0.16. In terms of profitability, HBP.TO's ROE is -0.22%, compared to APS.TO's ROE of +1.15%. Regarding short-term risk, HBP.TO is more volatile compared to APS.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check APS.TO's competition here
Tryp Therapeutics Inc. (CNQ: TRYP.CN)
HBP.TO vs TRYP.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, TRYP.CN has a market cap of 5.8M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while TRYP.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, HBP.TO's ROE is -0.22%, compared to TRYP.CN's ROE of +4.03%. Regarding short-term risk, HBP.TO is more volatile compared to TRYP.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check TRYP.CN's competition here
PharmaTher Holdings Ltd. (CNQ: PHRM.CN)
HBP.TO vs PHRM.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, PHRM.CN has a market cap of 5.5M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while PHRM.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas PHRM.CN's P/E ratio is -3.77. In terms of profitability, HBP.TO's ROE is -0.22%, compared to PHRM.CN's ROE of -1.55%. Regarding short-term risk, HBP.TO is more volatile compared to PHRM.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check PHRM.CN's competition here
Clearmind Medicine Inc. (CNQ: CMND.CN)
HBP.TO vs CMND.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, CMND.CN has a market cap of 5.1M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while CMND.CN trades at CA$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, HBP.TO's ROE is -0.22%, compared to CMND.CN's ROE of +21.24%. Regarding short-term risk, HBP.TO is more volatile compared to CMND.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check CMND.CN's competition here
Diagnamed Holdings Corp. (CNQ: DMED.CN)
HBP.TO vs DMED.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, DMED.CN has a market cap of 5.1M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while DMED.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas DMED.CN's P/E ratio is -3.94. In terms of profitability, HBP.TO's ROE is -0.22%, compared to DMED.CN's ROE of +7.40%. Regarding short-term risk, HBP.TO is less volatile compared to DMED.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check DMED.CN's competition here
GeneTether Therapeutics Inc. (CNQ: GTTX.CN)
HBP.TO vs GTTX.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, GTTX.CN has a market cap of 4.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while GTTX.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, HBP.TO's ROE is -0.22%, compared to GTTX.CN's ROE of -0.43%. Regarding short-term risk, HBP.TO is more volatile compared to GTTX.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check GTTX.CN's competition here
Gemina Laboratories Ltd. (CNQ: GLAB.CN)
HBP.TO vs GLAB.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, GLAB.CN has a market cap of 4.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while GLAB.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas GLAB.CN's P/E ratio is -1.50. In terms of profitability, HBP.TO's ROE is -0.22%, compared to GLAB.CN's ROE of +0.32%. Regarding short-term risk, HBP.TO is more volatile compared to GLAB.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check GLAB.CN's competition here
Awakn Life Sciences Corp. (NEO: AWKN.NE)
HBP.TO vs AWKN.NE Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, AWKN.NE has a market cap of 3.9M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while AWKN.NE trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, HBP.TO's ROE is -0.22%, compared to AWKN.NE's ROE of -4.29%. Regarding short-term risk, HBP.TO is more volatile compared to AWKN.NE. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check AWKN.NE's competition here
MYND Life Sciences Inc. (CNQ: MYND.CN)
HBP.TO vs MYND.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, MYND.CN has a market cap of 3.3M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while MYND.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas MYND.CN's P/E ratio is -6.21. In terms of profitability, HBP.TO's ROE is -0.22%, compared to MYND.CN's ROE of +0.36%. Regarding short-term risk, HBP.TO is less volatile compared to MYND.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check MYND.CN's competition here
Asep Medical Holdings Inc (CNQ: ASEP.CN)
HBP.TO vs ASEP.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, ASEP.CN has a market cap of 2.7M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while ASEP.CN trades at CA$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas ASEP.CN's P/E ratio is -2.18. In terms of profitability, HBP.TO's ROE is -0.22%, compared to ASEP.CN's ROE of -1.11%. Regarding short-term risk, HBP.TO is more volatile compared to ASEP.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check ASEP.CN's competition here
Intellipharmaceutics International Inc. (TSX: IPCI.TO)
HBP.TO vs IPCI.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, IPCI.TO has a market cap of 2.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while IPCI.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, HBP.TO's ROE is -0.22%, compared to IPCI.TO's ROE of +0.31%. Regarding short-term risk, HBP.TO is less volatile compared to IPCI.TO. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check IPCI.TO's competition here
Restart Life Sciences Corp. (CNQ: HEAL.CN)
HBP.TO vs HEAL.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, HEAL.CN has a market cap of 2.6M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while HEAL.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas HEAL.CN's P/E ratio is 55.12. In terms of profitability, HBP.TO's ROE is -0.22%, compared to HEAL.CN's ROE of -1.31%. Regarding short-term risk, HBP.TO is more volatile compared to HEAL.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check HEAL.CN's competition here
Grey Matters Health Inc. (CNQ: GREY.CN)
HBP.TO vs GREY.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, GREY.CN has a market cap of 2.5M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while GREY.CN trades at CA$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas GREY.CN's P/E ratio is -0.81. In terms of profitability, HBP.TO's ROE is -0.22%, compared to GREY.CN's ROE of N/A. Regarding short-term risk, HBP.TO is less volatile compared to GREY.CN. This indicates lower risk in terms of short-term price fluctuations for HBP.TO.Check GREY.CN's competition here
BioVaxys Technology Corp. (CNQ: BIOV.CN)
HBP.TO vs BIOV.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, BIOV.CN has a market cap of 2M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while BIOV.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas BIOV.CN's P/E ratio is -3.81. In terms of profitability, HBP.TO's ROE is -0.22%, compared to BIOV.CN's ROE of +0.70%. Regarding short-term risk, HBP.TO is more volatile compared to BIOV.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check BIOV.CN's competition here
Appili Therapeutics Inc. (TSX: APLI.TO)
HBP.TO vs APLI.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, APLI.TO has a market cap of 2M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while APLI.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas APLI.TO's P/E ratio is -0.47. In terms of profitability, HBP.TO's ROE is -0.22%, compared to APLI.TO's ROE of +0.27%. Regarding short-term risk, HBP.TO is more volatile compared to APLI.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check APLI.TO's competition here
Braxia Scientific Corp. (CNQ: BRAX.CN)
HBP.TO vs BRAX.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, BRAX.CN has a market cap of 1.4M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while BRAX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas BRAX.CN's P/E ratio is -0.30. In terms of profitability, HBP.TO's ROE is -0.22%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, HBP.TO is more volatile compared to BRAX.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check BRAX.CN's competition here
Entheon Biomedical Corp. (CNQ: ENBI.CN)
HBP.TO vs ENBI.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, ENBI.CN has a market cap of 1.4M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while ENBI.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas ENBI.CN's P/E ratio is -3.33. In terms of profitability, HBP.TO's ROE is -0.22%, compared to ENBI.CN's ROE of -0.79%. Regarding short-term risk, HBP.TO is more volatile compared to ENBI.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check ENBI.CN's competition here
HAVN Life Sciences Inc. (CNQ: HAVN.CN)
HBP.TO vs HAVN.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, HAVN.CN has a market cap of 1.2M. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while HAVN.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas HAVN.CN's P/E ratio is -0.00. In terms of profitability, HBP.TO's ROE is -0.22%, compared to HAVN.CN's ROE of -2.75%. Regarding short-term risk, HBP.TO is more volatile compared to HAVN.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check HAVN.CN's competition here
ChitogenX Inc. (CNQ: CHGX.CN)
HBP.TO vs CHGX.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, CHGX.CN has a market cap of 415.6K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while CHGX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas CHGX.CN's P/E ratio is -0.17. In terms of profitability, HBP.TO's ROE is -0.22%, compared to CHGX.CN's ROE of +0.19%. Regarding short-term risk, HBP.TO is more volatile compared to CHGX.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check CHGX.CN's competition here
Biocure Technology Inc. (CNQ: CURE.CN)
HBP.TO vs CURE.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, CURE.CN has a market cap of 408K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while CURE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, HBP.TO's ROE is -0.22%, compared to CURE.CN's ROE of -0.02%. Regarding short-term risk, HBP.TO is more volatile compared to CURE.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check CURE.CN's competition here
Albert Labs International Corp. (CNQ: ABRT.CN)
HBP.TO vs ABRT.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, ABRT.CN has a market cap of 372.1K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while ABRT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, HBP.TO's ROE is -0.22%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, HBP.TO is more volatile compared to ABRT.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check ABRT.CN's competition here
Nirvana Life Sciences Inc. (CNQ: NIRV.CN)
HBP.TO vs NIRV.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, NIRV.CN has a market cap of 337.6K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while NIRV.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas NIRV.CN's P/E ratio is 7.00. In terms of profitability, HBP.TO's ROE is -0.22%, compared to NIRV.CN's ROE of +0.21%. Regarding short-term risk, HBP.TO is more volatile compared to NIRV.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check NIRV.CN's competition here
WPD Pharmaceuticals Inc. (CNQ: WBIO.CN)
HBP.TO vs WBIO.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, WBIO.CN has a market cap of 324.8K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while WBIO.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas WBIO.CN's P/E ratio is -1000.00. In terms of profitability, HBP.TO's ROE is -0.22%, compared to WBIO.CN's ROE of +0.15%. Regarding short-term risk, HBP.TO is more volatile compared to WBIO.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check WBIO.CN's competition here
NanoSphere Health Sciences Inc. (CNQ: NSHS.CN)
HBP.TO vs NSHS.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, NSHS.CN has a market cap of 205.5K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while NSHS.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas NSHS.CN's P/E ratio is -0.85. In terms of profitability, HBP.TO's ROE is -0.22%, compared to NSHS.CN's ROE of +0.06%. Regarding short-term risk, HBP.TO is more volatile compared to NSHS.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check NSHS.CN's competition here
Algernon Pharmaceuticals Inc. (CNQ: AGN.CN)
HBP.TO vs AGN.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, AGN.CN has a market cap of 157.5K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while AGN.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas AGN.CN's P/E ratio is -0.06. In terms of profitability, HBP.TO's ROE is -0.22%, compared to AGN.CN's ROE of -0.93%. Regarding short-term risk, HBP.TO is more volatile compared to AGN.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check AGN.CN's competition here
Nova Mentis Life Science Corp. (CNQ: NOVA.CN)
HBP.TO vs NOVA.CN Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, NOVA.CN has a market cap of 148.3K. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while NOVA.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, HBP.TO's ROE is -0.22%, compared to NOVA.CN's ROE of -0.05%. Regarding short-term risk, HBP.TO is more volatile compared to NOVA.CN. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check NOVA.CN's competition here
Trillium Therapeutics Inc. (TSX: TRIL.TO)
HBP.TO vs TRIL.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, TRIL.TO has a market cap of 0. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while TRIL.TO trades at CA$23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, HBP.TO's ROE is -0.22%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, HBP.TO is more volatile compared to TRIL.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check TRIL.TO's competition here
InMed Pharmaceuticals Inc. (TSX: IN.TO)
HBP.TO vs IN.TO Comparison August 2026
Helix BioPharma Corp. (TSX: HBP.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBP.TO stands at 154.3M. In comparison, IN.TO has a market cap of 0. Regarding current trading prices, HBP.TO is priced at CA$1.97 on the TSX, while IN.TO trades at CA$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBP.TO currently has a P/E ratio of -45.91, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, HBP.TO's ROE is -0.22%, compared to IN.TO's ROE of -0.72%. Regarding short-term risk, HBP.TO is more volatile compared to IN.TO. This indicates higher risk in terms of short-term price fluctuations for HBP.TO.Check IN.TO's competition here